

RECEIVED

2006 NOV -9 A 11:31

OFFICE OF INTERNATIONAL  
CORPORATE FINANCE

6 November 2006

Ark Therapeutics Group plc  
79 New Cavendish Street  
London W1W 6XB

Phone: +44 (0) 20 7388 7722  
Fax: +44 (0) 20 7388 7805  
www.arktherapeutics.com

**BY COURIER**

US Securities and Exchange Commission  
Division of Corporate Finance  
Office of International Corporate Finance  
Mail Stop 3-2  
450 Fifth Street NW  
Washington DC 20549  
USA



06018327

**SUPPL**

Ark Therapeutics Group plc, Rule 12g3-2(b) Exemption, File No. 82-34804

To whom it may concern:

Please find enclosed information and/or documents furnished on behalf of Ark Therapeutics Group plc, Rule 12g3-2(b) File No. 82-34804, submitted pursuant to paragraph (b)(1)(iii) of Rule 12g3-2, which information shall not be deemed "filed" with the SEC or otherwise subject to the liabilities of Section 18 of the US Securities Exchange Act of 1934.

Sincerely,

Nick Plummer  
General Counsel & Company Secretary  
Ark Therapeutics Group plc

**PROCESSED**

NOV 14 2006

THOMSON  
FINANCIAL

<b>1.</b>	<b>DOCUMENTS MADE PUBLIC PURSUANT TO LAWS OF ENGLAND AND WALES SINCE SEPTEMBER 12, 2006</b>
1.1	Form 88(2) - Return of Allotment of Shares dated September 19, 2006
1.2	Form 88(2) - Return of Allotment of Shares dated September 28, 2006
1.3	Form 88(2) - Return of Allotment of Shares dated September 28, 2006
1.4	Form 88(2) - Return of Allotment of Shares dated October 2, 2006
1.5	Form 88(2) - Return of Allotment of Shares dated October 3, 2006
1.6	Form 88(2) - Return of Allotment of Shares dated November 6, 2006
1.7	Form 88(2) - Return of Allotment of Shares dated November 6, 2006
<b>2.</b>	<b>DOCUMENTS FILED WITH THE UKLA OR THE LSE (AND MADE PUBLIC THEREBY) SINCE SEPTEMBER 12, 2006</b>
2.1	<b>Miscellaneous Notifications filed with The London Stock Exchange</b>
2.1.1	Announcement dated September 27, 2006 regarding Research Update
2.1.2	Announcement dated October 2, 2006 regarding Holding(s) in Company
2.1.3	Announcement dated October 10, 2006 regarding Kerraboot
2.1.4	Announcement dated October 13, 2006 regarding Cerepro Patent Granted
<b>3.</b>	<b>PRESS RELEASES SINCE SEPTEMBER 12, 2006</b>
3.1	Press release dated September 27, 2006 regarding Research Update (see 2.1.1 above)
3.2	Press release dated October 10, 2006 regarding Kerraboot (see 2.1.3 above)
3.3	Press release dated October 13, 2006 regarding Cerepro Patent Granted (see 2.1.4 above)



**Companies House**  
for the record

# 88(2)

(Revised 2005)

Please complete in typescript, or  
in bold black capitals.

CHWP000

Company Number

4313987

Return of Allotment of Shares

Company name in full

ARK THERAPEUTICS GROUP PLC

Shares allotted (including bonus shares):

(see Guidance Booklet GBA6)

Date or period during which  
shares were allotted

(If shares were allotted on one date  
enter that date in the "from" box)

From

To

Day Month Year

Day Month Year

1 5 0 9 2 0 0 6

Class of shares

(ordinary or preference etc)

Number allotted

Nominal value of each share

Amount (if any) paid or due on each  
share (including any share premium)

ORDINARY	ORDINARY	ORDINARY	ORD.
31000	10000	10000	7500
£0.01	£0.01	£0.01	£0.01
£0.50	£0.69	£0.74	£0.605

List the names and addresses of the allottees and the  
number and class of shares allotted to each overleaf

If the allotted shares (including bonus shares) are fully or partly paid up otherwise than in  
cash please state:

% that each share is to be  
treated as paid up

% (if any) that each share  
is to be paid up in cash


Consideration for which  
the shares were allotted

(This information must be supported by  
the original or a certified copy of the  
contract or by Form 88(3) if the contract  
is not in writing)


Companies House receipt date barcode

This form has been provided free of charge  
by Companies House.

When you have completed and signed the form please send it to the  
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ

for companies registered in England and Wales

Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB

for companies registered in Scotland

DX 33050 Cardiff

DX 235 Edinburgh

or LP - 4 Edinburgh 2

09/2005

Shareholder details		Shares and share class allotted	
Name PERSHING KEEN NOMINEES LIMITED		Class of shares allotted	Number allotted
Address PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON UK Postcode E 1 4 2 B H		ORDINARY	58,500
Name 		Class of shares allotted	Number allotted
Address 			
UK Postcode			
Name 		Class of shares allotted	Number allotted
Address 			
UK Postcode			
Name 		Class of shares allotted	Number allotted
Address 			
UK Postcode			
Name 		Class of shares allotted	Number allotted
Address 			
UK Postcode			
Name 		Class of shares allotted	Number allotted
Address 			
UK Postcode			

Please enter the number of continuation sheets (if any) attached to this form

Signed

*N. Plummer*

Date

19/09/2006

~~Director / secretary / administrator / administrative receiver / receiver manager / receiver~~

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

Nick Plummer  
79 New Cavendish Street  
London  
W1W 6XB

Tel: 0207 388 7722

## Return of Allotment of Shares

Please complete in typescript, or  
in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS GROUP PLC

### Shares allotted (including bonus shares):

Date or period during which  
shares were allotted

(If shares were allotted on one date  
enter that date in the "from" box)

From

Day Month Year

2 5 0 9 2 0 0 6

To

Day Month Year

Class of shares

(ordinary or preference etc)

ORDINARY

Number allotted

6250

Nominal value of each share

£0.01

Amount (if any) paid or due on each  
share (including any share premium)

50p

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be  
treated as paid up

--	--	--

Consideration for which  
the shares were allotted

(This information must be supported by  
the duly stamped contract or by the duly  
stamped particulars on Form 88(3) if the  
contract is not in writing)


When you have completed and signed the form send it to  
the Registrar of Companies at:

Companies House receipt date barcode

This form has been provided free of charge  
by Companies House.

Companies House, Crown Way, Cardiff CF14 3UZ  
For companies registered in England and Wales

DX 33050 Cardiff

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB  
For companies registered in Scotland

DX 235  
Edinburgh

Shareholder details		Shares and share class allotted	
Name <u>PERSHING KEEN NOMINEES LIMITED</u> <hr/> Address <u>PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT</u> <u>CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON</u> <hr/> UK Postcode <u>E 1 4 L 2 B H</u>		Class of shares allotted <u>ORDINARY</u> <hr/> <hr/>	Number allotted <u>6,250</u> <hr/> <hr/>
Name <u></u> <hr/> Address <u></u> <hr/> <hr/> UK Postcode <u> L L L L L L L</u>		Class of shares allotted <hr/> <hr/>	Number allotted <hr/> <hr/>
Name <u></u> <hr/> Address <u></u> <hr/> <hr/> UK Postcode <u> L L L L L L L</u>		Class of shares allotted <hr/> <hr/>	Number allotted <hr/> <hr/>
Name <u></u> <hr/> Address <u></u> <hr/> <hr/> UK Postcode <u> L L L L L L L</u>		Class of shares allotted <hr/> <hr/>	Number allotted <hr/> <hr/>
Name <u></u> <hr/> Address <u></u> <hr/> <hr/> UK Postcode <u> L L L L L L L</u>		Class of shares allotted <hr/> <hr/>	Number allotted <hr/> <hr/>

Please enter the number of continuation sheets (if any) attached to this form

Signed

*MB Williams*

Date

*28/9/06*

A director / secretary / administrator / administrative receiver / receiver manager / receiver

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

Nick Plummer  
Ark Therapeutics Group plc  
79 New Cavendish Street  
London W1W 6XB

Tel: 0207 388 7722


## Return of Allotment of Shares

Please complete in typescript, or  
in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS GROUP PLC

## Shares allotted (including bonus shares):

Date or period during which  
shares were allotted

(If shares were allotted on one date  
enter that date in the "from" box)

From

Day Month Year

2 6 0 9 2 0 0 6

To

Day Month Year

Class of shares

(ordinary or preference etc)

ORDINARY

ORDINARY

ORDINARY

Number allotted

2000

1000

1000

Nominal value of each share

£0.01

£0.01

£0.01

Amount (if any) paid or due on each  
share (including any share premium)

74p

50p

60.5p

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be  
treated as paid up

--	--	--

Consideration for which  
the shares were allotted

(This information must be supported by  
the duly stamped contract or by the duly  
stamped particulars on Form 88(3) if the  
contract is not in writing)


When you have completed and signed the form send it to  
the Registrar of Companies at:

Companies House receipt date barcode

This form has been provided free of charge  
by Companies House.

Companies House, Crown Way, Cardiff CF14 3UZ  
For companies registered in England and Wales

DX 33050 Cardiff

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB  
For companies registered in Scotland

DX 235  
Edinburgh

Shareholder details		Shares and share class allotted	
Name PERSHING KEEN NOMINEES LIMITED <hr/> Address PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON <hr/> UK Postcode E 1 4 L 2 B H		Class of shares allotted <hr/> ORDINARY <hr/> <hr/>	Number allotted <hr/> 4,000 <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> <hr/> UK Postcode L L L L L L L		Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> <hr/> UK Postcode L L L L L L L		Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> <hr/> UK Postcode L L L L L L L		Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>
Name <hr/> Address <hr/> <hr/> <hr/> UK Postcode L L L L L L L		Class of shares allotted <hr/> <hr/> <hr/>	Number allotted <hr/> <hr/> <hr/>

Please enter the number of continuation sheets (if any) attached to this form

Signed

*MB Williams*

Date

28/9/06

A director / secretary / administrator / administrative receiver / receiver manager / receiver

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

Nick Plummer  
Ark Therapeutics Group plc  
79 New Cavendish Street  
London W1W 6XB

Tel: 0207 388 7722






**Companies House**

*for the record*

# 88(2)

## Return of Allotment of Shares

Please complete in typescript, or  
in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS GROUP PLC

### Shares allotted (including bonus shares):

Date or period during which  
shares were allotted

(If shares were allotted on one date  
enter that date in the "from" box)

From

Day Month Year

2 7 0 9 2 0 0 6

To

Day Month Year

Class of shares

(ordinary or preference etc)

ORDINARY

Number allotted

5000

Nominal value of each share

£0.01

Amount (if any) paid or due on each  
share (including any share premium)

0.605p

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be  
treated as paid up

--	--	--

Consideration for which  
the shares were allotted

(This information must be supported by  
the duly stamped contract or by the duly  
stamped particulars on Form 88(3) if the  
contract is not in writing)


When you have completed and signed the form send it to  
the Registrar of Companies at:

Companies House, Crown Way, Cardiff CF14 3UZ  
For companies registered in England and Wales

DX 33050 Cardiff

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB  
For companies registered in Scotland

DX 235  
Edinburgh

Companies House receipt date barcode

This form has been provided free of charge  
by Companies House.

Shareholder details		Shares and share class allotted	
<b>Name</b> PERSHING KEEN NOMINEES LIMITED <b>Address</b> PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON UK Postcode E 1 4 L 2 B H		<b>Class of shares allotted</b> ORDINARY	<b>Number allotted</b> 5,000
<b>Name</b> <b>Address</b> UK Postcode		<b>Class of shares allotted</b>	<b>Number allotted</b>
<b>Name</b> <b>Address</b> UK Postcode		<b>Class of shares allotted</b>	<b>Number allotted</b>
<b>Name</b> <b>Address</b> UK Postcode		<b>Class of shares allotted</b>	<b>Number allotted</b>
<b>Name</b> <b>Address</b> UK Postcode		<b>Class of shares allotted</b>	<b>Number allotted</b>

Please enter the number of continuation sheets (if any) attached to this form

Signed

*Nick Plummer*  
~~Director~~ Secretary ~~Administrator~~ ~~Administrative receiver~~ ~~Receiver manager~~ ~~Receiver~~

Date

02/10/2016

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

Nick Plummer  
Ark Therapeutics Group plc  
79 New Cavendish Street  
London W1W 6XB

Tel: 0207 388 7722

## Return of Allotment of Shares

Please complete in typescript, or  
in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS GROUP PLC

## Shares allotted (including bonus shares):

Date or period during which  
shares were allotted

(If shares were allotted on one date  
enter that date in the "from" box)

From

Day Month Year

2 9 0 9 2 0 0 6

To

Day Month Year

Class of shares

(ordinary or preference etc)

ORDINARY

Number allotted

25000

Nominal value of each share

£0.01

Amount (if any) paid or due on each  
share (including any share premium)

50p

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be  
treated as paid up

--	--	--

Consideration for which  
the shares were allotted

(This information must be supported by  
the duly stamped contract or by the duly  
stamped particulars on Form 88(3) if the  
contract is not in writing)


When you have completed and signed the form send it to  
the Registrar of Companies at:

Companies House, Crown Way, Cardiff CF14 3UZ  
For companies registered in England and Wales

DX 33050 Cardiff

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB  
For companies registered in Scotland

DX 235  
Edinburgh

Companies House receipt date barcode

This form has been provided free of charge  
by Companies House.

Shareholder details		Shares and share class allotted	
Name <u>PERSHING KEEN NOMINEES LIMITED</u> <hr/> Address <u>PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT</u> <u>CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON</u> <hr/> UK Postcode <u>E 1 4 2 B H</u>		Class of shares allotted <u>ORDINARY</u>	Number allotted <u>25,000</u>
Name _____ <hr/> Address _____ <hr/> <hr/> UK Postcode <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u>		Class of shares allotted _____	Number allotted _____
Name _____ <hr/> Address _____ <hr/> <hr/> UK Postcode <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u>		Class of shares allotted _____	Number allotted _____
Name _____ <hr/> Address _____ <hr/> <hr/> UK Postcode <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u>		Class of shares allotted _____	Number allotted _____
Name _____ <hr/> Address _____ <hr/> <hr/> UK Postcode <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u> <u>  </u>		Class of shares allotted _____	Number allotted _____

Please enter the number of continuation sheets (if any) attached to this form

Signed

Nick Plummer  
~~director~~ / secretary / administrator / administrative receiver / receiver manager / receiver

Date

03/10/2026

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

☐ Nick Plummer  
☐ Ark Therapeutics Group plc  
☐ 79 New Cavendish Street  
☐ London W1W 6XB  
☐ Tel: 0207 388 7722



Companies House

for the record

# 88(2)

## Return of Allotment of Shares

Please complete in typescript, or  
in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS GROUP PLC

### Shares allotted (including bonus shares):

Date or period during which  
shares were allotted

(If shares were allotted on one date  
enter that date in the "from" box)

From

To

Day Month Year

Day Month Year

3 1 1 0 2 0 0 6

Class of shares

(ordinary or preference etc)

ORDINARY

Number allotted

20250

Nominal value of each share

£0.01

Amount (if any) paid or due on each  
share (including any share premium)

0.50p

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be  
treated as paid up

Consideration for which  
the shares were allotted

(This information must be supported by  
the duly stamped contract or by the duly  
stamped particulars on Form 88(3) if the  
contract is not in writing)

When you have completed and signed the form send it to  
the Registrar of Companies at:

Companies House, Crown Way, Cardiff CF14 3UZ — DX 33050 Cardiff  
For companies registered in England and Wales

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB  
For companies registered in Scotland

DX 235  
Edinburgh

Companies House receipt date barcode

This form has been provided free of charge  
by Companies House.

Shareholder details		Shares and share class allotted	
Name <u>PERSHING KEEN NOMINEES LIMITED</u> Address <u>PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT</u> <u>CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON</u> UK Postcode <u>E 1 4 2 B H</u>		Class of shares allotted <u>ORDINARY</u> Number allotted <u>20,250</u>	
Name _____ Address _____ UK Postcode _____		Class of shares allotted _____ Number allotted _____	
Name _____ Address _____ UK Postcode _____		Class of shares allotted _____ Number allotted _____	
Name _____ Address _____ UK Postcode _____		Class of shares allotted _____ Number allotted _____	
Name _____ Address _____ UK Postcode _____		Class of shares allotted _____ Number allotted _____	

Please enter the number of continuation sheets (if any) attached to this form

Signed

*Nf C Plummer*

Date

*06/11/2006*

~~A director~~ secretary / administrator / administrative receiver / receiver manager / receiver

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

Nick Plummer  
Ark Therapeutics Group plc  
79 New Cavendish Street  
London W1W 6XB

Tel: 0207 388 7722




Companies House

for the record

# 88(2)

## Return of Allotment of Shares

Please complete in typescript, or  
in bold black capitals.

CHWP000

Company Number

4313987

Company name in full

ARK THERAPEUTICS GROUP PLC

### Shares allotted (including bonus shares):

Date or period during which  
shares were allotted

(If shares were allotted on one date  
enter that date in the "from" box)

From

Day Month Year

0 2 1 1 2 0 0 6

To

Day Month Year

--	--	--	--	--	--	--	--

Class of shares

(ordinary or preference etc)

ORDINARY

Number allotted

16000

Nominal value of each share

£0.01

Amount (if any) paid or due on each  
share (including any share premium)

69p

List the names and addresses of the allottees and the number of shares allotted to each overleaf

If the allotted shares are fully or partly paid up otherwise than in cash please state:

% that each share is to be  
treated as paid up

--	--	--

Consideration for which  
the shares were allotted

(This information must be supported by  
the duly stamped contract or by the duly  
stamped particulars on Form 88(3) if the  
contract is not in writing)


When you have completed and signed the form send it to  
the Registrar of Companies at:

Companies House receipt date barcode

This form has been provided free of charge  
by Companies House.

Companies House, Crown Way, Cardiff CF14 3UZ  
For companies registered in England and Wales

DX 33050 Cardiff

Companies House, 37 Castle Terrace, Edinburgh EH1 2EB  
For companies registered in Scotland

DX 235  
Edinburgh

Shareholder details		Shares and share class allotted	
Name <u>PERSHING KEEN NOMINEES LIMITED</u> Address <u>PARTICIPANT ID 601 MEMBER ACCOUNT LDCLT</u> <u>CAPSTAN HSE, ONE CLOVE CRESCENT, EAST INDIA DOCK, LONDON</u> UK Postcode <u>E 1 4 2 B H</u>		Class of shares allotted <u>ORDINARY</u> Number allotted <u>16,000</u>	
Name _____ Address _____ UK Postcode <u>  L  L  L  L  L  L  L  </u>		Class of shares allotted _____ Number allotted _____	
Name _____ Address _____ UK Postcode <u>  L  L  L  L  L  L  L  </u>		Class of shares allotted _____ Number allotted _____	
Name _____ Address _____ UK Postcode <u>  L  L  L  L  L  L  L  </u>		Class of shares allotted _____ Number allotted _____	
Name _____ Address _____ UK Postcode <u>  L  L  L  L  L  L  L  </u>		Class of shares allotted _____ Number allotted _____	

Please enter the number of continuation sheets (if any) attached to this form

Signed

*Nick Plummer*

Date

*06/11/2006*

~~/A director/~~ secretary ~~/administrator/~~ administrative receiver ~~/receiver manager/~~ receiver

Please delete as appropriate

Please give the name, address, telephone number and, if available, a DX number and Exchange of the person Companies House should contact if there is any query.

Nick Plummer  
Ark Therapeutics Group plc  
79 New Cavendish Street  
London W1W 6XB

Tel: 0207 388 7722




## Regulatory Announcement

Go to market news section



Company	Ark Therapeutics Group PLC
TIDM	AKT
Headline	Research Update
Released	07:00 27-Sep-06
Number	5199J

### Ark Announces UK Launch of Flaminal® Woundcare Treatment

#### *New anti-microbial gel effective against MRSA*

London, UK, 27 September 2006 - Ark Therapeutics Group plc ("Ark" or the "Company") today announces that it is to launch Flaminal®, a topical anti-microbial wound care gel, in the UK on 1<sup>st</sup> October. Flaminal® will be sold to hospitals and community nurses through Ark's existing UK salesforce which currently promotes Kerraboot®, the Company's novel device for the treatment of diabetic and venous leg ulcers. The launch follows Ark's success in securing price reimbursement from the UK NHS Business Service Authority, announced earlier in the year.

Flaminal®, which Ark has in-licensed from FlenPharma of Belgium, is a new non-cytotoxic<sup>(1)</sup> alginate gel with anti-microbial properties utilising a novel enzyme system. This gel is indicated for wounds which show delayed healing as a result of a local infection or high bacterial load. To date, clinical data has shown that Flaminal® has up to three times the healing rate<sup>(2)</sup> compared with existing products<sup>(3,4)</sup>. Flaminal® is particularly effective against *Streptococcus pyogenes* and methicillin-resistant *Staphylococcus aureus* (MRSA)<sup>(5)</sup>, two of the most troublesome and difficult to manage pathogens in wound care.

Flaminal® will be made available in two formulations, Flaminal® for wet wounds and Flaminal® Hydro for drier wounds. The product will be positioned in the anti-microbial segment of the UK advanced wound care market, which is currently valued in excess of £30 million and has grown by more than 50%<sup>(6)</sup> over the last two years. Flaminal® will offer a novel alternative to the silver-based treatments that currently dominate the market.

Flaminal® is listed in the October edition of the UK Drug Tariff at a price of £6.99 per 15g tube.

Commenting on today's announcement, Paul Higham, Ark's Commercial Director, said:

*"Flaminal® is a highly differentiated wound care product, with a novel mode of action backed by strong clinical data. It is particularly effective in preventing acquired wound infection and therefore promoting wound healing. Its launch is another development in our long-term strategy of building a stand-alone wound care business in the UK, which we will continue to strengthen through further in-licensing and the development of our own products."*

#### Notes

- (1) D Van den Plas et al., Flaminal® Hydro combines non-cytotoxicity with antimicrobial activity, Wounds UK 2005.
- (2) Reduction in area of ulcer after four weeks' treatment
- (3) de la Brassinne M, Thirion L, Horvat LI. A novel method of comparing the healing properties of two hydrogels in chronic leg ulcers. J Eur Acad Dermatol Venereol. 2006 Feb;20(2):131-5.

- (4) Scanlon E, Karlsmark T, Leaper DJ, Carter K, Poulsen PB, Hart-Hansen K, Hahn TW. Cost-effective faster wound healing with a sustained silver-releasing foam dressing in delayed healing leg ulcers – a health-economic analysis. *Int Wound J* 2005; 2:150-160
- (5) Source: FlenPharma *in vitro* data
- (6) Source: TNS Independent market data

**For further information please contact:**

**Ark Therapeutics Group plc: +44 (0)20 7388 7722**

Dr Nigel Parker, Chief Executive

Martyn Williams, Chief Financial Officer

**Financial Dynamics: +44 (0)20 7831 3113**

David Yates

Anna Keeble

#### **Notes to Editors**

#### **Flaminal® and Flaminal® Hydro**

Flaminal® and Flaminal® Hydro contain proprietary biological anti-microbial enzyme systems providing protection from infections without toxicity to human cells. They maintain the wound in a humid environment, continuously debride the wound, restore bacterial balance and are both non-cytotoxic and hypoallergenic.

Flaminal® is indicated for the following wounds:

Highly exuding ulcers, oncologic wounds, second degree burns, post-operative wounds, pre-operative fibrinous wounds and bed sores.

Flaminal® Hydro is indicated for the following wounds:

Dermatosurgery, moderately exuding ulcers, second degree burns and post-operative, moderately exuding wounds.

Flaminal® and Flaminal® Hydro are CE-marked within the EU and approved for sale in China, Switzerland and Saudi Arabia.

#### **FlenPharma**

FlenPharma, established in November 2000, is a private Belgian company specialising in developing innovative and advanced treatments for wounds. FlenPharma's laboratories are based at Edegem, adjacent to the Antwerp University Hospital and University campus.

#### **Ark Therapeutics Group plc**

Ark is a specialist healthcare group (the "Group"), addressing high value areas of clear unmet medical need. With one marketed product, Kerraboot®, and three further lead products in late stage clinical development: Vitor™, Cerepro™ and Trinam®, the Group is transitioning from an R&D focused company to a commercial, revenue generating business. Capitalising on over ten years of research in vascular biology and gene-based medicine, Ark has a broad product portfolio targeted at specific unmet clinical needs within vascular disease, wound care and cancer. These are large and growing markets, where opportunities exist for effective new products to generate significant revenues. Cerepro™ is on track to becoming one of the world's first commercially available gene-based medicines.

Ark's existing products are sourced from related but largely non-dependent technologies within the Group and have been selected to enable them to be taken through development within the Group's own means and to benefit from Orphan Drug Status and/or Fast Track Designation, as appropriate. This strategy has allowed the Group to retain greater value and greater control of clinical development timelines, and to mitigate the risks of dependency on any one particular programme or development partner. Ark has secured patents or has patent applications pending for all its lead products in principal pharmaceutical markets.

Ark has its origins in businesses established in the mid-1990s by Professor John Martin and Mr Stephen Barker of University College London and Professor Seppo Ylä-Herttuala of the AI Virtanen Institute at the

Ark's shares were first listed on the London Stock Exchange in March 2004 (AKT.L).

*This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Ark's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.*

END

**Close**

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2006 London Stock Exchange plc. All rights reserved

# Regulatory Announcement

Go to market news section



Company Ark Therapeutics Group PLC  
TIDM AKT  
Headline Holding(s) in Company  
Released 15:49 02-Oct-06  
Number 8143J

RNS Number:8143J  
Ark Therapeutics Group PLC  
02 October 2006

## NOTIFICATION OF MAJOR INTERESTS IN SHARES

1) NAME OF COMPANY

Ark Therapeutics Group plc

2) NAME OF SHAREHOLDER HAVING A MAJOR INTEREST

Aberforth Smaller Companies Trust plc

3) Please state whether notification indicates that it is in respect of holding of the Shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

As 2 above

4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them.

Nortrust Nominees Limited A/C ABERFRTH

5) Number of shares acquired.

Not advised

6) Percentage of issued Class

Not advised

7) Number of shares disposed

Not advised

8) Percentage of issued Class

Not advised

9) Class of security

Ordinary shares

10) Date of transaction

Not advised

11) Date company informed

2 October 2006

12) Total holding following this notification

5,209,332

13) Total percentage holding of issued class following this notification

3.27%

14) Any additional information

15) Name of contact and telephone number for queries

Nick Plummer - +44(0)207.388 7722

16) Name and signature of authorised company official responsible for making this notification

Nick Plummer - Company Secretary

17) Date of Notification

2 October 2006

This information is provided by RNS  
The company news service from the London Stock Exchange

END

Close

**London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.**

©2006 London Stock Exchange plc. All rights reserved

## Regulatory Announcement

Go to market news section



Company	Ark Therapeutics Group PLC
TIDM	AKT
Headline	Re: Kerraboot
Released	07:00 10-Oct-06
Number	2065K

### Ark Therapeutics Group plc

#### Ark Announces Kerraboot® Entry into US Market

**10 October 2006, London UK:** Ark Therapeutics Group plc ("Ark" or the "Company") today announces that its devices subsidiary, Patient Plus Limited, has signed a pilot distribution and marketing agreement with the US medical products distributor, Health Care Logistics Inc. ("HCL") for Kerraboot®, Ark's novel wound care device for the management of leg and foot ulcers.

This exclusive agreement, initially for one year, will establish first sales of Kerraboot® in the US and will allow Ark to obtain data supporting the health economic benefits of Kerraboot® for this market. In Europe, it has been demonstrated that the use of Kerraboot® in patients with diabetic leg and foot ulcers can result in a reduction in total healthcare costs of up to 48%<sup>1</sup>. Under this pilot agreement, HCL will access its established healthcare customers in the Eastern US Seaboard States<sup>2</sup>, including hospitals, nursing homes, long term care centres and home health agencies. Ark will supply Kerraboot® at an agreed "cost-plus" transfer price to HCL and will also provide corporate product support and assistance in establishing usage with certain key US opinion leaders who have expressed an interest in the product. Sales through this arrangement are expected to make a positive financial contribution to Ark during the initial period. Kerraboot® is already listed by the FDA for marketing and the US patent for the product was granted to Ark earlier this year.

Lower leg and foot ulceration affects around 1% of the adult population in the developed world<sup>3</sup> and is particularly prevalent amongst the diabetic population, where the ulcers can develop rapidly and are particularly difficult to heal. The US is estimated to have a potential target market of 270,000 leg and foot ulcer patients suitable for Kerraboot® at any one time<sup>4</sup>.

Paul Higham, Commercial Director at Ark, commented:

"We are very pleased to announce this agreement with HCL. We believe they offer the right capabilities to facilitate the entry of Kerraboot® into the US market and allow us to start building a data package which will demonstrate both the economic advantages of the product to US payers and confirm its clinical benefits to patients. We look forward to working together with them".

**For further information please contact:**

**Ark Therapeutics +44 (0)20 7388 7722**  
Dr Nigel Parker, Chief Executive Officer  
Martyn Williams, Chief Financial Officer

**Financial Dynamics +44 (0)20 7831 3113**  
David Yates / Anna Keeble

**Notes to Editors**

## Sources:

- <sup>1</sup> Company cost utility model based on published data.
- <sup>2</sup> Connecticut, Delaware, Rhode Island, Massachusetts, Maine, New York, New Jersey, Maryland, Ohio, Virginia, West Virginia, Vermont, New Hampshire and Pennsylvania.
- <sup>3</sup> Briggs M, Nelson EA: Topical agents or dressings for pain in venous leg ulcers; The Cochrane Library, Issue 1, 2002
- <sup>4</sup> Company estimates based on patient populations and composite references.

## Kerraboot®

Kerraboot® provides a new approach to the management of foot and leg ulcers, in the form of a novel, non pressurised, boot-like dressing device, which is simple, quick and mostly pain free to change. Kerraboot® facilitates the draining and isolation of exudates, such as matrix metalloproteases, which inhibit angiogenesis, from the ulcer. This allows natural growth factors, such as Vascular Endothelial Growth Factors (VEGF), to stimulate healing. In clinical studies of ulcers managed with Kerraboot®, reductions in ulcer size of up to 60% has been observed over the four-week study period, with both healthcare professionals and patients expressing a strong preference for Kerraboot® over existing treatments. These UK-based studies have also shown that management of ulcers with Kerraboot®, which does not involve any additional dressings, can be extremely cost effective, saving up to 50% of nurse time and with patients often becoming nurse independent.

## Health Care Logistics, Inc.

HCL is a privately owned US Corporation, established in 1978, engaged in the sales and marketing of niche healthcare products and with annual revenues of \$48 million. HCL has 19,000 customers and covers 98% of all US hospitals. 60% of HCL's revenue sales are from hospitals, followed by drug stores and nursing homes. The Company has a 60,000 sq ft headquarter facility in Circleville, Ohio, a 110,000 sq ft Distribution & Logistics Centre in Grove City, Ohio and a 40,000 sq ft Sales and Service centre in Galloway, Ohio. The Company has 175 employees of which 60 are sales and service representatives.

## Ark Therapeutics Group plc and Patient Plus Ltd.

Patient Plus Ltd is a wholly owned subsidiary of Ark Therapeutics Group plc, a specialist healthcare group (the "Group") addressing high value areas of unmet medical need within vascular disease, wound care and cancer. These are large and growing markets, where opportunities exist for effective new products to generate significant revenues. With two marketed devices, Kerraboot® and Flaminal®, and three further lead pharmaceutical products in late stage clinical development: Cerepro™, Vitor™, and Trinam®, the Group is transitioning from an R&D company to a commercial, revenue generating business.

Ark's own products are sourced from related but largely non-dependent technologies within the Group and have been selected to enable them to be taken through development within the Group's own means and to benefit from Orphan Drug Status and/or Fast Track Designation, as appropriate. This strategy has allowed the Group to retain greater value and greater control of clinical development timelines, and to mitigate the risks of dependency on any one particular programme or development partner. Ark has secured patents or has patent applications pending for all its lead products in principal pharmaceutical markets.

Ark has its origins in businesses established in the mid-1990s by Professor John Martin and Mr Stephen Barker of University College London and Professor Seppo Ylä-Herttuala of the AI Virtanen Institute at the University of Kuopio, Finland, all of whom play leading roles in the Company's research and development programmes.

Ark's shares were first listed on the London Stock Exchange in March 2004 (AKT.L).

*This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could*

*cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Ark's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.*

END

Close

**London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.**

©2006 London Stock Exchange plc. All rights reserved



## Regulatory Announcement

Go to market news section



<b>Company</b>	Ark Therapeutics Group PLC
<b>TIDM</b>	AKT
<b>Headline</b>	Cerepro Patent Granted
<b>Released</b>	07:00 13-Oct-06
<b>Number</b>	4129K

### Ark Therapeutics Group plc

#### European Patent Granted for Cerepro™

**13 October 2006, London UK:** Ark Therapeutics Group plc ("Ark" or the "Company") today announces that the European Patent Office has granted the Company a patent covering the use of Cerepro™, its novel gene-based medicine for the treatment of operable high grade glioma (brain cancer). The patent grant gives protection in Europe until November 2019. Cerepro™ has already been granted patent protection in the USA, Australia, Mexico and China.

Cerepro™ is one of the first gene-based medicines to undergo full development. Post-operative treatment with Cerepro™ produces an average extension of 7.5 months of life, giving around 15.5 months survival in a disease where patients will on average only live for around eight months. Cerepro™ is currently undergoing regulatory review for marketing approval in Europe. The application was submitted to the European regulatory authority, the EMEA, by Ark in the second half of last year and responses to the first series of questions raised by the EMEA's scientific committee were recently filed by the Company. The outcome of the EMEA's review is expected by early 2007. Ark has also commenced a corroborative Phase III/IV study for Cerepro™ (Study 904), which is being undertaken in approximately 40 centres in Europe and Israel and aims to recruit up to 250 patients.

Cerepro™ has Orphan Drug Status in Europe and the USA. It is manufactured by Ark in its facility in Finland, the first factory ever to be approved to manufacture gene-based medicines for commercial supply in Europe.

Nigel Parker, Chief Executive of Ark, commented: "We are pleased to have received this European patent grant for Cerepro™ which means we now have patent protection in the three largest potential markets. Recently we have seen substantial progress in the breakthrough area of gene based-medicines, where their potential to contribute to improved healthcare is increasingly recognised. With Cerepro™ demonstrating that it is able almost to double average patient survival time, the product offers significant hope to patients who develop this devastating disease. We look forward to updating investors on Cerepro's further development progress in due course."

#### For further information please contact:

**Ark Therapeutics +44 (0)20 7388 7722**  
Dr Nigel Parker, Chief Executive Officer  
Martyn Williams, Chief Financial Officer

**Financial Dynamics +44 (0)20 7831 3113**  
David Yates / Anna Keeble

#### Notes to Editors

##### Malignant glioma

Malignant glioma is a devastating and fatal form of brain tumour that is usually confined to the brain. The current standard therapy involves surgically removing the solid tumour mass (when possible) and initiating radiotherapy and/or chemotherapy. Even with the latest approved treatments, most patients die within one year of diagnosis, with average survival being about eight months. Little therapeutic progress has been made in recent years and the prognosis for malignant glioma patients is poor. A high unmet clinical need exists for

new treatments that prolong life in this devastating disease. There are approximately 16,000 cases of malignant glioma in the EU which are operable.

## Cerepro™

Cerepro™ is an adenoviral mediated gene based medicine (ad.HSV tk) given by multiple injections into the healthy brain tissue of patients following surgical removal of the solid tumour mass. In the following days, ganciclovir, is given intravenously. Once treated, healthy brain cells surrounding the site where the tumour was removed express the enzyme thymidine kinase. This converts the ganciclovir to a substance which specifically kills dividing cells. The healthy neurones surrounding the tumour in the brain are non-dividing and are therefore not susceptible to this substance. In this way Cerepro™, harnesses healthy brain cells to help prevent a new tumour from growing.

## Ark Therapeutics Group plc

Ark Therapeutics Group plc, is a specialist healthcare group (the "Group"), addressing high value areas of unmet medical need within vascular disease, wound care and cancer. These are large and growing markets, where opportunities exist for effective new products to generate significant revenues. With two marketed devices, Kerraboot®, and Flaminal®, and three further lead pharmaceutical products in late stage clinical development: Cerepro™, Vitor™, and Trinam®, the Group is transitioning from an R&D company to a commercial, revenue generating business.

Ark's own products are sourced from related but largely non-dependent technologies within the Group and have been selected to enable them to be taken through development within the Group's own means and to benefit from Orphan Drug Status and/or Fast Track Designation, as appropriate. This strategy has allowed the Group to retain greater value and greater control of clinical development timelines, and to mitigate the risks of dependency on any one particular programme or development partner. Ark has secured patents or has patent applications pending for all its lead products in principal pharmaceutical markets.

Ark has its origins in businesses established in the mid-1990s by Professor John Martin and Mr Stephen Barker of University College London and Professor Seppo Ylä-Herttuala of the AI Virtanen Institute at the University of Kuopio, Finland, all of whom play leading roles in the Company's research and development programmes.

Ark's shares were first listed on the London Stock Exchange in March 2004 (AKT.L).

*This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Ark's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.*

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2006 London Stock Exchange plc. All rights reserved